CTLA4 and melanoma: Researchers have detected the expression of MHC class I and class II proteins on the surface of tumor cells in 181 untreated melanoma patients, analyzed their transcription levels and genomes, and investigated the relationship between MHC and the clinical response to anti‐CTLA‐4 therapy, anti‐PD‐1 therapy or combined treatment.